Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2015

View Archived Issues

New clamp assay detects mutational spectrum of a tumor in patient serum

Astellas review progress of first quarter of fiscal 2015

Lilly reports FFAR1 agonists

Sorrento Therapeutics licenses ex-Chinese rights to Mabtech Ltd biologics

GSK reviews progress of late-stage pipeline in second quarter 2015

Novartis patents SHP-2 inhibitors

University of California, Oakland, presents prodrugs of RTC-13

Sarmont discloses NO donors

Cadila Healthcare reports development of lipid lowering agents

BrightGene Bio-Medical Technology develops folate receptor ligands

Viewpoint Molecular Targeting and RadioMedix secure NCI grant for image guided therapy

Baxalta board rejects unsolicited acquisition proposal from Shire

New findings suggest therapeutic potential of Cirara to reduce edema in ischemic stroke

Antares Pharma starts phase III trial of subcutaneous testosterone in hypogonadism

FDA awards fast track designation to Marina Biotech's CEQ-508 for FAP

RVT-101 improves cognition and function as an adjunct therapy to donepezil

La Jolla Pharmaceutical enters exclusive license agreements for LJPC-30Sa and LJPC-30Sb

AstraZeneca licenses adenosine A2A receptor antagonist from Heptares Therapeutics

Endo sells men's health businesses to Boston Scientific and plans to reorganise Litha

ISIS Pharmaceuticals presents preliminary data for ISIS-TTRRx

Diurnal and National Institutes of Health's CRADA extended

Coferon describes bivalent Bcr-Abl tyrosine kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...